Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy | Zendy

Zhenshu Xu | Zendy; Shundong Cang | Zendy; Ting Yang | Zendy; Delong Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy

Author(s) -

Zhenshu Xu,

Shundong Cang,

Ting Yang,

Delong Liu

Publication year - 2009

Publication title -

hematology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.239

H-Index - 12

ISSN - 2038-8330

DOI - 10.4081/hr.2009.e4

Subject(s) - nilotinib , dasatinib , medicine , imatinib , cardiotoxicity , chronic myelogenous leukemia , tyrosine kinase , tyrosine kinase inhibitor , concomitant , pharmacology , oncology , leukemia , toxicity , myeloid leukemia , cancer , receptor

Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them, are largely unclear. For example, relative to dasatinib and nilotinib, severe congestive heart failure and left ventricular dysfunction are rare but prominent with imatinib treatment, particularly in patients receiving higher doses (>600 mg/day). In comparison with imatinib, prolongation of the QT interval is relatively common in patients treated with either dasatinib or nilotinib. In contrast to nilotinib, pericardial effusions are observed with both imatinib and dasatinib. It is suggested that these data, an evaluation of cardiac status, use of concomitant medications, and potential risk factors should be considered in the management of CML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research